AngioDynamics (NASDAQ:ANGO) Updates FY 2027 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2027 earnings guidance on Tuesday. The company provided EPS guidance of -0.290–0.240 for the period, compared to the consensus EPS estimate of -0.190. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $328.7 million.

Analyst Ratings Changes

Several analysts have recently commented on the company. Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Finally, Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

AngioDynamics Stock Up 1.8%

Shares of AngioDynamics stock opened at $13.00 on Wednesday. The business has a fifty day simple moving average of $12.07 and a 200 day simple moving average of $11.32. The stock has a market cap of $537.16 million, a PE ratio of -17.33 and a beta of 0.34. AngioDynamics has a 12 month low of $8.36 and a 12 month high of $13.99.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The firm had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts expect that AngioDynamics will post -0.23 EPS for the current fiscal year.

AngioDynamics News Roundup

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics posted record fiscal Q4 and full-year 2026 results, highlighting strong execution and med-tech growth. AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
• Positive Sentiment: The company reported a smaller-than-expected quarterly loss of $0.07 per share versus a consensus loss of $0.11, while revenue of $86.61 million beat estimates of $80.24 million. AngioDynamics earnings report and conference call
• Positive Sentiment: Fiscal 2027 revenue guidance of $336 million to $341 million came in above Wall Street expectations, signaling management confidence in continued growth. AngioDynamics posts record Q4 and fiscal 2026 results
• Neutral Sentiment: Analysts’ price targets were revised higher, reflecting improved sentiment after the earnings release. Brokerages Set AngioDynamics, Inc. (NASDAQ:ANGO) PT at $18.67
• Negative Sentiment: Despite the earnings beat, AngioDynamics still expects a FY 2027 EPS loss, so profitability remains a work in progress. AngioDynamics posts record Q4 and fiscal 2026 results

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its position in shares of AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock worth $2,434,000 after purchasing an additional 22,658 shares during the period. Jane Street Group LLC boosted its holdings in shares of AngioDynamics by 267.1% in the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after buying an additional 34,054 shares during the period. Legal & General Group Plc increased its position in shares of AngioDynamics by 279.5% during the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after acquiring an additional 9,098 shares in the last quarter. Rhumbline Advisers increased its position in shares of AngioDynamics by 4.3% during the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after acquiring an additional 2,510 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of AngioDynamics by 15.8% during the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock worth $960,000 after acquiring an additional 13,217 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.